Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, Powis J, Litwin AH, Cooper C, Dalgard O, Hellard M, Bruggmann P, Marks P, Lacombe K, Stedman C, Read P, Hajarizadeh B, Dunlop AJ, Conway B, Feld JJ, Dore GJ, Grebely J, SIMPLIFY and D3FEAT Study Groups
Hepatitis C
"Tell us what's going on": Exploring the information needs of pregnant and post-partum women in Australia during the pandemic with 'Tweets', 'Threads', and women's views.
Caddy C, Cheong M, Lim MSC, Power R, Vogel JP, Bradfield Z, Coghlan B, Homer CSE, Wilson AN
Maternal, Newborn + Child Health COVID-19
Changes in needle and syringe presentations point to the successes of Australian harm reduction policy and practice.
O'Keefe D, Jacka D, Maher L
Injecting Drug Use
A Microtubule-Associated Protein Is Essential for Malaria Parasite Transmission.
Wichers-Misterek JS, Binder AM, Mesén-Ramírez P, Dorner LP, Safavi S, Fuchs G, Lenz TL, Bachmann A, Wilson D, Frischknecht F, Gilberger TW
Malaria
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Wines BD, Kurtovic L, Trist HM, Esparon S, Lopez E, Chappin K, Chan LJ, Mordant FL, Lee WS, Gherardin NA, Patel SK, Hartley GE, Pymm P, Cooney JP, Beeson JG, Godfrey DI, Burrell LM, van Zelm MC, Wheatley AK, Chung AW, Tham WH, Subbarao K, Kent SJ, Hogarth PM
COVID-19